Caris Life Sciences: A Closer Look at Opportunities, Roadblocks for Widespread Adoption of AI-Based Precision Oncology Tools

Published on Sep 02, 2025

Caris Life Sciences (CAI) earned Food and Drug Administration (FDA) approval for MI Cancer Seek, a tool that runs genetic sequencing on tumor tissue, for use as a companion diagnostic—atest that helps identify the best course of treatment for a patient—in November 2024. Since then, the company has touted the product, which incorporates artificial intelligence […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.